Evaluation of the Cost-Effectiveness of Dexrazoxane for the Prevention of Anthracycline-Related Cardiotoxicity in Children With Sarcoma and Haematologic Malignancies: A European Perspective

Cost Effectiveness and Resource Allocation - United Kingdom
doi 10.1186/s12962-020-0205-4
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly

Current Pharmaceutical Design
Drug DiscoveryPharmacology
2010English

Cost-Effectiveness Analysis of Parenting Interventions for the Prevention of Behaviour Problems in Children

PLoS ONE
Multidisciplinary
2019English

Anthracycline Extravasation Injuries: Management With Dexrazoxane

Therapeutics and Clinical Risk Management
2009English

Anthracycline Cardiotoxicity

2012English

Cost-Effectiveness of Atypical Antipsychotics for the Treatment of Relapse Prevention for Bipolar Disorder: The Russian Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Managing Anthracycline-Induced Cardiotoxicity: Beginning With the End in Mind

Future Cardiology
Molecular MedicineCardiovascular MedicineCardiology
2015English

Cardiotoxicity of Anthracycline Therapy: Current Perspectives

Archives of Medical Science
Medicine
2016English

Role of Nebivolol in Anthracycline-Induced Cardiotoxicity

International Journal of Research in Medical Sciences
2019English

Risk Factors for Anthracycline-Associated Cardiotoxicity

Supportive Care in Cancer
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy